Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Cocrystal Pharma Inc COCP

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function... see more

NDAQ:COCP - Post Discussion

Cocrystal Pharma Inc > Q3 EPS: Pipeline Remains on Track
View:
Post by schoolofrock on Nov 17, 2020 10:53am

Q3 EPS: Pipeline Remains on Track

Comment by Popeye82 on Apr 27, 2021 12:45pm
https://www.cocrystalpharma.com/news/press-releases/detail/114/cocrystal-pharma-extends-drug-discovery-collaboration-with
Comment by Popeye82 on Apr 27, 2021 1:01pm
https://www.cocrystalpharma.com/news/press-releases/detail/115/cocrystal-pharma-reports-2020-financial-results-provides
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities